vs

Side-by-side financial comparison of ENANTA PHARMACEUTICALS INC (ENTA) and Zepp Health Corp (ZEPP). Click either name above to swap in a different company.

ENANTA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($18.6M vs $10.5M, roughly 1.8× Zepp Health Corp). Zepp Health Corp runs the higher net margin — -2.1% vs -64.1%, a 62.0% gap on every dollar of revenue. Over the past eight quarters, ENANTA PHARMACEUTICALS INC's revenue compounded faster (4.5% CAGR vs -7.9%).

Enanta Pharmaceuticals Inc is a clinical-stage biotechnology company that develops innovative antiviral therapies for infectious diseases including hepatitis B virus, respiratory syncytial virus (RSV), and SARS-CoV-2. It operates primarily in the U.S. and global markets, partnering with pharmaceutical firms to advance its small molecule drug candidate pipeline for patients with unmet medical needs.

Zepp Health Corp is a global digital health and smart wearable technology company. It develops and sells fitness trackers, smartwatches, and AI-powered health monitoring tools, serving individual consumers, sports teams, and healthcare providers across Asia, North America, and Europe, with core focus on wellness tracking and remote health management solutions.

ENTA vs ZEPP — Head-to-Head

Bigger by revenue
ENTA
ENTA
1.8× larger
ENTA
$18.6M
$10.5M
ZEPP
Higher net margin
ZEPP
ZEPP
62.0% more per $
ZEPP
-2.1%
-64.1%
ENTA
Faster 2-yr revenue CAGR
ENTA
ENTA
Annualised
ENTA
4.5%
-7.9%
ZEPP

Income Statement — Q1 FY2026 vs Q3 FY2025

Metric
ENTA
ENTA
ZEPP
ZEPP
Revenue
$18.6M
$10.5M
Net Profit
$-11.9M
$-223.0K
Gross Margin
38.2%
Operating Margin
-60.5%
-1.2%
Net Margin
-64.1%
-2.1%
Revenue YoY
9.8%
Net Profit YoY
46.4%
EPS (diluted)
$-0.42
$-0.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ENTA
ENTA
ZEPP
ZEPP
Q4 25
$18.6M
Q3 25
$15.1M
$10.5M
Q2 25
$18.3M
$8.2M
Q1 25
$14.9M
$5.3M
Q4 24
$17.0M
Q3 24
$14.6M
$5.9M
Q2 24
$18.0M
$5.6M
Q1 24
$17.1M
$5.5M
Net Profit
ENTA
ENTA
ZEPP
ZEPP
Q4 25
$-11.9M
Q3 25
$-18.7M
$-223.0K
Q2 25
$-18.3M
$-1.1M
Q1 25
$-22.6M
$-2.7M
Q4 24
$-22.3M
Q3 24
$-28.8M
$-1.8M
Q2 24
$-22.7M
$-1.5M
Q1 24
$-31.2M
$-2.0M
Gross Margin
ENTA
ENTA
ZEPP
ZEPP
Q4 25
Q3 25
38.2%
Q2 25
36.2%
Q1 25
37.3%
Q4 24
Q3 24
40.6%
Q2 24
40.3%
Q1 24
36.8%
Operating Margin
ENTA
ENTA
ZEPP
ZEPP
Q4 25
-60.5%
Q3 25
-121.6%
-1.2%
Q2 25
-103.2%
-10.3%
Q1 25
-164.3%
-47.7%
Q4 24
-138.8%
Q3 24
-204.4%
-29.5%
Q2 24
-134.6%
-24.3%
Q1 24
-192.1%
-39.6%
Net Margin
ENTA
ENTA
ZEPP
ZEPP
Q4 25
-64.1%
Q3 25
-123.6%
-2.1%
Q2 25
-99.7%
-13.0%
Q1 25
-151.7%
-51.2%
Q4 24
-131.4%
Q3 24
-197.3%
-31.2%
Q2 24
-126.1%
-26.7%
Q1 24
-182.7%
-36.8%
EPS (diluted)
ENTA
ENTA
ZEPP
ZEPP
Q4 25
$-0.42
Q3 25
$-0.88
$-0.01
Q2 25
$-0.85
$-0.07
Q1 25
$-1.06
$-0.17
Q4 24
$-1.05
Q3 24
$-1.36
$-0.01
Q2 24
$-1.07
$-0.01
Q1 24
$-1.47
$-0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ENTA
ENTA
ZEPP
ZEPP
Cash + ST InvestmentsLiquidity on hand
$37.4M
$8.7M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$126.6M
$31.2M
Total Assets
$329.5M
$80.9M
Debt / EquityLower = less leverage
0.31×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ENTA
ENTA
ZEPP
ZEPP
Q4 25
$37.4M
Q3 25
$32.3M
$8.7M
Q2 25
$44.8M
$7.8M
Q1 25
$60.2M
$10.7M
Q4 24
$84.3M
Q3 24
$37.2M
$16.4M
Q2 24
$35.8M
$17.0M
Q1 24
$63.5M
$17.9M
Total Debt
ENTA
ENTA
ZEPP
ZEPP
Q4 25
Q3 25
$9.6M
Q2 25
$9.7M
Q1 25
$9.6M
Q4 24
Q3 24
$5.7M
Q2 24
$7.3M
Q1 24
$11.2M
Stockholders' Equity
ENTA
ENTA
ZEPP
ZEPP
Q4 25
$126.6M
Q3 25
$64.7M
$31.2M
Q2 25
$79.3M
$31.1M
Q1 25
$93.5M
Q4 24
$111.8M
Q3 24
$128.8M
Q2 24
$148.9M
$44.6M
Q1 24
$166.1M
Total Assets
ENTA
ENTA
ZEPP
ZEPP
Q4 25
$329.5M
Q3 25
$280.7M
$80.9M
Q2 25
$301.0M
$75.8M
Q1 25
$323.0M
$71.6M
Q4 24
$348.6M
Q3 24
$376.7M
$81.3M
Q2 24
$398.8M
$79.7M
Q1 24
$413.6M
$80.5M
Debt / Equity
ENTA
ENTA
ZEPP
ZEPP
Q4 25
Q3 25
0.31×
Q2 25
0.31×
Q1 25
Q4 24
Q3 24
Q2 24
0.16×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ENTA
ENTA
ZEPP
ZEPP
Operating Cash FlowLast quarter
$-11.7M
Free Cash FlowOCF − Capex
$-11.8M
FCF MarginFCF / Revenue
-63.6%
Capex IntensityCapex / Revenue
0.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-18.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ENTA
ENTA
ZEPP
ZEPP
Q4 25
$-11.7M
Q3 25
$-6.5M
Q2 25
$17.5M
Q1 25
$-13.5M
Q4 24
$-16.8M
Q3 24
$-10.4M
Q2 24
$-14.8M
Q1 24
$-28.6M
Free Cash Flow
ENTA
ENTA
ZEPP
ZEPP
Q4 25
$-11.8M
Q3 25
$-7.9M
Q2 25
$17.4M
Q1 25
$-16.0M
Q4 24
$-25.5M
Q3 24
$-19.4M
Q2 24
$-21.3M
Q1 24
$-30.3M
FCF Margin
ENTA
ENTA
ZEPP
ZEPP
Q4 25
-63.6%
Q3 25
-52.5%
Q2 25
94.7%
Q1 25
-107.4%
Q4 24
-150.6%
Q3 24
-132.5%
Q2 24
-118.6%
Q1 24
-177.5%
Capex Intensity
ENTA
ENTA
ZEPP
ZEPP
Q4 25
0.8%
Q3 25
9.6%
Q2 25
0.8%
Q1 25
17.0%
Q4 24
51.6%
Q3 24
61.3%
Q2 24
36.4%
Q1 24
9.8%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons